Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion
Cancer Medicine · 2025
DOI: 10.1002/cam4.70696 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Benjamin D Mercier und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Patient Selection, Eligibility Determination, Urologic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
In a joint statement, Friends of Cancer Research and the American Society of Clinical Oncology affirmed the need for broadening clinical trial eligibility criteria to expand patient access to investigational treatments and enroll cohorts more representative of the general population. Our study aimed to characterize and analyze the prevalence of overly exclusionary eligibility criteria in contemporary clinical trials involving patients with locally advanced and metastatic urothelial cancer.
Methods
Utilizing MeSH query terms “(metastatic OR advanced OR stage IV OR unresectable) AND (bladder cancer OR upper tract urothelial carcinoma OR upper tract urothelial cancer)” in ClinicalTrials.gov , we identified 205 interventional urothelial cancer trials activated between June 30, 2012 through June 30, 2022. We investigated the prevalence of four potentially restrictive criteria: the presence of brain metastases, HIV infection, hepatitis B/C infection, and the presence of concurrent malignancies. Fisher's Exact test was utilized to ascertain significant associations between criteria and trial characteristics.
Results
Of 205 trials found initially, 37 (18%) contained sufficient data for analysis. Overall, HIV infection and Hepatitis B/C infection were most restrictive, with most trials completely excluding patients with these conditions (89.2%; 56.8%). Restrictiveness for HIV infection and type of therapy were significantly associated, with most exclusionary trials involving combination or immunotherapies (39.4%; 33.3%; p = 0.003). Brain metastases were totally excluded by 35.1% of trials and had 18.9% of trials provide no explicit criteria or guidelines. Most trials specified conditions for the inclusion of patients with concurrent malignancies (91.9%). Variant histology was also underrepresented, with most trials not specifying or totally excluding all variant histology (43.2%; 8.1%).
Conclusion
HIV infection and hepatitis B/C infection were commonly identified in exclusion criteria across these trials despite limited evidence suggesting these criteria significantly impact therapy efficacy and tolerability. Broadening and modernization of eligibility criteria will ensure more inclusive clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Department of Medical Oncology, City of Hope Orange County Medical Center, Irvine, California, USA.
ORCID-Profile: Benjamin D Mercier, Ameish Govindarajan, Daniela V Castro, Kyle O Lee, Nazli Dizman, Sumanta K Pal
Zitieren
APA
Mercier, B. D., Govindarajan, A., Castro, D. V., Li, X., Philip, E. J., Feng, M. I., Prajapati, S. R., Chan, E. H., Lee, K. O., Sehgal, I., Patel, J., O'Dell, A., Chehrazi-Raffle, A., Ebrahimi, H., Rock, A., Zengin, Z. B., Meza, L. A., Dizman, N., Hsu, J., …, & Tripathi, A. (2025). Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. Cancer Medicine. https://doi.org/10.1002/cam4.70696
Vancouver
Mercier BD, Govindarajan A, Castro DV, Li X, Philip EJ, Feng MI, et al. Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion. Cancer Medicine. 2025. doi:10.1002/cam4.70696
BibTeX
@article{Mercier2025,
author = {Mercier, Benjamin D and Govindarajan, Ameish and Castro, Daniela V and Li, Xiaochen and Philip, Errol J and Feng, Matthew I and Prajapati, Sweta R and Chan, Elyse H and Lee, Kyle O and Sehgal, Ishaan and Patel, Jalen and O'Dell, Anna and Chehrazi-Raffle, Alexander and Ebrahimi, Hedyeh and Rock, Adam and Zengin, Zeynep Busra and Meza, Luis A and Dizman, Nazli and Hsu, JoAnn and Liu, Sandy and Dorff, Tanya B and Pal, Sumanta K and Tripathi, Abhishek},
title = {Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70696}
}
EUVIMED